Research articlePublished 2013
Incomplete Success of Angioinhibitor Therapy in Cancer: Estimation of Contribution of Pro-angiogenic Activity of Patient Thyroid Hormone
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Despite the obvious promise of the strategy, pharmaceutical angioinhibition has had variable success in clinical cancer management. Thyroid hormone is a potent pro-angiogenic factor. Endogenous circulating levels of proangiogenic thyroid hormone in cancer patients treated with anti-angiogenic drugs may contribute to host resistance to angioinhibition and explain, at least in part, the variable cancer chemotherapeutic responses obtained with anti-angiogenic agents. The chick chorioallantoic membrane (CAM) angiogenesis assay accepts human tumor xenografts and is a system in which individual patient blood samples can be tested in xenograft vasculature for anti-angiogenic content—including thyroid hormone—in the presence of angioinhibitory drug dose escalation. The assay may also be used to screen individual patient tumor biopsy xenografts for susceptibility to angioinhibition.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Paul J Davis”
- BylineArticles whose byline prints “Murat Yalcin”
- BylineArticles whose byline prints “Hung-Yun Lin”
- BylineArticles whose byline prints “Heng-Yuan Tang”
- BylineArticles whose byline prints “Aleck Hercbergs”
- BylineArticles whose byline prints “John T. Leith”
- BylineArticles whose byline prints “Faith B Davis”
- BylineArticles whose byline prints “Mary K Luidens”
